This paper provides a brief summary of our recent work on the heterogeneity of estradiol binding sites in mammary tumors of the mouse and human. Mammary tumors from both species contain the classical estrogen receptor and a second site(s) which we call type II. These type II sites are found in the cytoplasmic and nuclear compartments of both tumors, and can interfere with the measurement of estrogen receptors. The function of type II sites is not known; however, an assessment of these sites in conjunction with an accurate measurement of the estrogen receptor may provide a clearer picture of the true hormone dependence of breast tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF01806234DOI Listing

Publication Analysis

Top Keywords

mammary tumors
12
binding sites
8
sites mammary
8
estrogen receptor
8
type sites
8
measurement estrogen
8
sites
6
tumors
5
heterogeneity estrogen
4
estrogen binding
4

Similar Publications

Obesity is a modifiable risk factor for breast cancer. Yet, how obesity contributes to cancer initiation is not fully understood. The goal of this study was to determine if the body mass index (BMI) and metabolic hallmarks of obesity are related to DNA damage in normal breast tissue.

View Article and Find Full Text PDF

Introduction: Doxorubicin is a chemotherapeutic drug used to treat various cancers. Exercise training (ET) can attenuate some cardiotoxic effects of doxorubicin (DOX) in tumor-free animals. However, the ET effects on cardiac function and glucose metabolism in DOX-treated breast cancer models remain unclear.

View Article and Find Full Text PDF

β-Glucuronidase-Responsive Albumin-Binding Prodrug of Colchicine-Site Binders for Selective cancer Therapy.

ChemMedChem

January 2025

UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers, groupe « Systèmes Moléculaires Programmés », Faculté des Sciences Fondamentales et Appliquées, 4 rue Michel Brunet, TSA 51106, 86073, Poitiers, FRANCE.

The development of novel therapeutic strategies enabling the selective destruction of tumors while sparing healthy tissues is of great interest to improve the efficacy of cancer chemotherapy. In this context, we designed a β-glucuronidase-responsive albumin-binding prodrug programmed to release a potent Isocombretastatin A-4 analog within the tumor microenvironment. When injected at a non-toxic dose in mice bearing orthotopic triple-negative mammary tumors, this prodrug produced a significant anticancer activity, therefore offering a valuable alternative to the systemic administration of the parent drug.

View Article and Find Full Text PDF

Uncommon metastatic journey: unusual breast metastases of medullary thyroid carcinoma: a case report.

BMC Womens Health

January 2025

Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Boulevad 9 Avril Bab Saadoun 1006, Tunis, Tunisia.

Medullary thyroid carcinoma is a neuroendocrine tumor derived from thyroid C-cells. It is a rare aggressive tumor, known to metastasize to lymph nodes, liver, bones, and lungs. We report a case of a young patient with a family history of breast cancer, who developed breast metastases six months post-treatment for medullary thyroid carcinoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!